{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:12:54Z","timestamp":1791497574934,"version":"4.3.4"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.biopha.2017.10.116","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T01:34:40Z","timestamp":1509932080000},"page":"624-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Tetrandrine and cancer \u2013 An overview on the molecular approach"],"prefix":"10.1016","volume":"97","author":[{"given":"Bhagya","family":"N.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekar","family":"K.R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.10.116_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd2155","article-title":"Why is cancer drug discovery so difficult?","volume":"6","author":"Kamb","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/np030096l","article-title":"Natural products as sources of new drugs over the period 1981\u20132002","volume":"66","author":"Newman","year":"2003","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.biopha.2017.10.116_bib0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0025","series-title":"Mechanisms of Anticancer Drugs","first-page":"34","author":"Payne","year":"2008"},{"key":"10.1016\/j.biopha.2017.10.116_bib0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc723","article-title":"Natural products in cancer chemotherapy: past, present and future","volume":"2","author":"Mann","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jep.2005.05.011","article-title":"Plants as a source of anti-cancer agents","volume":"100","author":"Cragg","year":"2005","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrc3017","article-title":"Molecular targets of phytochemicals for cancer prevention","volume":"11","author":"Lee","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/toxins2040517","article-title":"Phytochemicals in cancer prevention and therapy: truth or dare?","volume":"2","author":"Russo","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.biopha.2017.10.116_bib0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrc1189","article-title":"Cancer chemoprevention with dietary phytochemicals","volume":"3","author":"Surh","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0055","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2174\/187152012803833026","article-title":"Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability","volume":"12","author":"Wang","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.phytochem.2016.02.005","article-title":"Tetrandrine\u2013a molecule of wide bioactivity","volume":"125","author":"Bhagya","year":"2016","journal-title":"Phytochemistry"},{"key":"10.1016\/j.biopha.2017.10.116_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.1998.tb00341.x","article-title":"Tetrandrine","volume":"19","author":"Huang","year":"1998","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.biopha.2017.10.116_bib0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jep.2010.08.047","article-title":"The genus Stephania (Menispermaceae): chemical and pharmacological perspectives","volume":"132","author":"Semwal","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0075","series-title":"Chinese Drugs of Plant Origin","author":"Tang","year":"1992"},{"key":"10.1016\/j.biopha.2017.10.116_bib0080","series-title":"Compendium of Materia Medica (Pen-Ts\u2019ao-Kang-Mu). Originally Published in 1596: Reprinted as Fang-Chi Herb Book XVIII","first-page":"761","author":"Li","year":"1994"},{"key":"10.1016\/j.biopha.2017.10.116_bib0085","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/S0021-9258(18)69196-3","article-title":"Interaction of tetrandrine with slowly inactivating calcium channels: characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin","volume":"263","author":"King","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tips.2004.01.009","article-title":"Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation","volume":"25","author":"Wang","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2017.10.116_bib0095","first-page":"1102","article-title":"Potential role of tetrandrine in cancer therapy","volume":"23","author":"Chen","year":"2002","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2017.10.116_bib0100","first-page":"332","article-title":"Newer non-steroidal anti-inflammatory drugs\u2013a review of their therapeutic potential and adverse drug reactions","volume":"3","author":"Dhikav","year":"2002","journal-title":"JIACM"},{"key":"10.1016\/j.biopha.2017.10.116_bib0105","doi-asserted-by":"crossref","first-page":"40800","DOI":"10.18632\/oncotarget.8315","article-title":"Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2017.10.116_bib0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0120","first-page":"871","article-title":"Cell cycle control as a basis for cancer drug development","volume":"16","author":"McDonald","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0125","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.biopha.2017.10.116_bib0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2017.10.116_bib0135","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.1074\/jbc.M114.631820","article-title":"Novel role for \u03b3-catenin in the regulation of cancer cell migration via the induction of hepatocyte growth factor activator inhibitor type 1 (HAI-1)","volume":"290","author":"Sechler","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0140","doi-asserted-by":"crossref","first-page":"e0154323","DOI":"10.1371\/journal.pone.0154323","article-title":"Plakoglobin reduces the in vitro growth, migration and invasion of ovarian cancer cells expressing N-cadherin and mutant p53","volume":"11","author":"Alaee","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2017.10.116_bib0145","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrm1493","article-title":"Checking on DNA damage in S phase","volume":"5","author":"Bartek","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.39.1.295","article-title":"Cyclins and cell cycle checkpoints","volume":"39","author":"Johnson","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2017.10.116_bib0160","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1073\/pnas.94.7.2776","article-title":"The cell cycle and cancer","volume":"94","author":"Collins","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.biopha.2017.10.116_bib0165","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/0092-8674(89)90508-4","article-title":"The retinoblastoma protein is phosphorylated during specific phases of the cell cycle","volume":"58","author":"Buchkovich","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2017.10.116_bib0170","series-title":"Molecular Biology of the Cell","first-page":"10001","author":"Alberts","year":"2002"},{"key":"10.1016\/j.biopha.2017.10.116_bib0175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/excr.1996.0356","article-title":"Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation","volume":"229","author":"Nigg","year":"1996","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X","article-title":"Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors","volume":"69","author":"Courjal","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0185","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/138955706777934955","article-title":"Advances in mitotic inhibitors for cancer treatment","volume":"6","author":"Jiang","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clml.2013.07.008","article-title":"Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression","volume":"14","author":"Sewify","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2017.10.116_bib0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11418-013-0765-0","article-title":"Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells","volume":"68","author":"Chen","year":"2014","journal-title":"J. Nat. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0024-3205(03)00266-2","article-title":"Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells","volume":"73","author":"Kuo","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2017.10.116_bib0205","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1158\/0008-5472.CAN-04-0313","article-title":"Tetrandrine induces early G1 arrest in human colon carcinoma cells by down- regulating the activity and inducing the degradation of G1-S\u2013specific Cyclin-Dependent Kinases and by inducing p53 and p21Cip1","volume":"64","author":"Meng","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3892\/ijo.2014.2735","article-title":"Tetrandrine induces G1\/S cell cycle arrest through the ROS\/Akt pathway in EOMA cells and inhibits angiogenesis in vivo","volume":"46","author":"Xiao","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0215","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3892\/or.2013.2352","article-title":"Tetrandrine inhibits hepatocellular carcinoma cell growth through the caspase pathway and G2\/M phase","volume":"29","author":"Yu","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2017.10.116_bib0220","doi-asserted-by":"crossref","first-page":"21458","DOI":"10.1074\/jbc.M109.094797","article-title":"7, 3\u2019, 4\u2019- trihydroxyisoflavone inhibits epidermal growth factor\u2013induced proliferation and transformation of JB6 P + mouse epidermal cells by suppressing cyclin-dependant kinases and phospahtidylinositol 3-kinase","volume":"285","author":"Lee","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0225","first-page":"1239","article-title":"Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells","volume":"21","author":"Lee","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1142\/S0192415X06003692","article-title":"Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines","volume":"34","author":"Ng","year":"2006","journal-title":"J. Chin. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0235","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4161\/cbt.7.7.6142","article-title":"Involvement of PI3 K\/AKT\/GSK3\u03b2 pathway in tetrandrine-induced G1 arrest and apoptosis","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2017.10.116_bib0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"Alao","year":"2007","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0245","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4161\/cc.8.6.7889","article-title":"DNA damage-dependent cyclin D1 proteolysis: GSK3\u03b2 holds the smoking gun","volume":"8","author":"Pontano","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2017.10.116_bib0250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature13079","article-title":"Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus","volume":"508","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2017.10.116_bib0255","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"24","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0260","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.pharmtox.41.1.367","article-title":"Cellular responses to DNA damage","volume":"41","author":"Norbury","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","article-title":"Cell death: the significance of apoptosis","volume":"68","author":"Wyllie","year":"1980","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00005-012-0205-y","article-title":"Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer","volume":"61","author":"Chaabane","year":"2013","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.biopha.2017.10.116_bib0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at the cellular level","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0280","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/252754a0","article-title":"Association of mammalian cell death with a specific endonucleolytic degradation of DNA","volume":"252","author":"Williams","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2017.10.116_bib0285","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.cdd.4402103","article-title":"The CASBAH: a searchable database of caspase substrates","volume":"14","author":"Luthi","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2017.10.116_bib0290","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35037710","article-title":"The biochemistry of apoptosis","volume":"407","author":"Hengartner","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2017.10.116_bib0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2017.10.116_bib0300","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/carcin\/21.3.485","article-title":"Apoptosis in cancer","volume":"21","author":"Lowe","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2017.10.116_bib0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1677\/erc.0.0060029","article-title":"Prognostic significance of apoptosis regulators in breast cancer","volume":"6","author":"Krajewski","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0310","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","article-title":"Evading apoptosis in cancer","volume":"23","author":"Fernald","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0315","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm0302-274","article-title":"Tumor-cell resistance to death receptor\u2013induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax","volume":"8","author":"LeBlanc","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/path.1532","article-title":"Inactivating mutation of the pro-apoptotic gene BID in gastric cancer","volume":"202","author":"Lee","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4161\/cbt.1.1.45","article-title":"Differential inactivation of caspase-8 in lung cancers","volume":"1","author":"Shivapurkar","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2017.10.116_bib0330","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/sj.onc.1206727","article-title":"Inactivating mutations of CASPASE-7 gene in human cancers","volume":"22","author":"Soung","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2017.10.116_bib0335","first-page":"879","article-title":"Promoting apoptosis as a strategy for cancer drug discovery","volume":"5","author":"Fesik","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0345","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1007\/s13277-016-4950-0","article-title":"A novel derivative of tetrandrine (H1) induces endoplasmic reticulum stress-mediated apoptosis and prosurvival autophagy in human non-small cell lung cancer cells","volume":"37","author":"Lin","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0350","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ptr.1435","article-title":"Tetrandrine induces apoptosis in hepatic stellate cells","volume":"18","author":"Zhao","year":"2004","journal-title":"Phytother. Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0355","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2174\/092986711795029708","article-title":"Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe","volume":"18","author":"Delmas","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0360","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"Kaufmann","year":"2000","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0365","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2008.03.059","article-title":"Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids","volume":"268","author":"Liu","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.10.116_bib0370","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.25817","article-title":"Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma","volume":"129","author":"Liu","year":"2011","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.biopha.2017.10.116_bib0375","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/bph.13045","article-title":"Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21","volume":"172","author":"Mei","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0380","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/aps.2013.62","article-title":"ROS generated by CYP450 especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes","volume":"34","author":"Qi","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2017.10.116_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0076486","article-title":"Tetrandrine induces mitochondria-mediated apoptosis in human gastric cancer BGC-823 cells","volume":"8","author":"Qin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2017.10.116_bib0390","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3701-5-4","article-title":"Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species","volume":"5","author":"Wang","year":"2015","journal-title":"Cell Biosci."},{"key":"10.1016\/j.biopha.2017.10.116_bib0395","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4103\/1008-682X.142134","article-title":"Tetrandrine suppresses proliferation induces apoptosis, and inhibits migration and invasion in human prostate cancer cells","volume":"17","author":"Liu","year":"2015","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.biopha.2017.10.116_bib0400","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2009.06.009","article-title":"Tetrandrine induces apoptosis and growth suppression of colon cells in mice","volume":"287","author":"Wu","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.10.116_bib0405","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.bi.62.070193.004223","article-title":"Function and regulation of ras","volume":"62","author":"Lowy","year":"1993","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0410","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signaling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0415","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0962-8924(00)01740-2","article-title":"Understanding ras \u2018it ain\u2019t over \u2018til it\u2019s over\u2019","volume":"10","author":"Shields","year":"2000","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0420","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3748\/wjg.v10.i18.2735","article-title":"ADAM17 mRNA expression and pathological features of hepatocellular carcinoma","volume":"10","author":"Ding","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0425","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2017.10.116_bib0430","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1083\/jcb.200307137","article-title":"Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands","volume":"164","author":"Sahin","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0435","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s13277-013-1293-y","article-title":"Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17","volume":"35","author":"Wu","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0440","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910640412","article-title":"Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas","volume":"64","author":"Bellacosa","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0445","doi-asserted-by":"crossref","first-page":"23589","DOI":"10.1074\/jbc.270.40.23589","article-title":"Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions","volume":"270","author":"Albanese","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0450","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2017.10.116_bib0455","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of Tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2017.10.116_bib0460","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0465","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1172\/JCI76094","article-title":"Targeting cancer with kinase inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2017.10.116_bib0470","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting ras signaling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0475","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.7314\/APJCP.2014.15.16.6463","article-title":"The mTOR signaling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals","volume":"15","author":"Tan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2017.10.116_bib0480","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4142\/jvs.2009.10.1.23","article-title":"Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells","volume":"10","author":"Cho","year":"2009","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.biopha.2017.10.116_bib0485","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/265061","article-title":"Tetrandrine suppresses cancer angiogenesis and metastasis in 4T1 tumor bearing mice","author":"Gao","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0490","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1038\/sj.onc.1207556","article-title":"Mitogen-activated protein kinases in apoptosis regulation","volume":"23","author":"Wada","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2017.10.116_bib0495","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bjc.2013.334","article-title":"Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)\/Akt signalling","volume":"109","author":"Wan","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0500","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2017.10.116_bib0505","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.biopha.2017.10.116_bib0510","first-page":"4575","article-title":"Mutant ras oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis","volume":"55","author":"Rak","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0515","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrclinonc.2012.120","article-title":"Cancer prevention by targeting angiogenesis","volume":"9","author":"Albini","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0520","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.24208","article-title":"Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats","volume":"124","author":"Chen","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0525","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(16)30104-8","article-title":"Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial","volume":"17","author":"Goto","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0530","first-page":"385","article-title":"Synergistic antiangiogenic activity of tetrandrine combined with endostar on the human umbilical vein endothelial cell model","volume":"28","author":"Qian","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.biopha.2017.10.116_bib0535","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrm4024","article-title":"Autophagy at the crossroads of catabolism and anabolism","volume":"16","author":"Kaur","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0540","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc1692","article-title":"The role of autophagy in cancer development and response to therapy","volume":"5","author":"Kondo","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0545","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","article-title":"The role of autophagy in cancer: therapeutic implications","volume":"10","author":"Yang","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2017.10.116_bib0550","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1666","article-title":"Autophagy: dual roles in life and death?","volume":"6","author":"Baehrecke","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0555","doi-asserted-by":"crossref","first-page":"35576","DOI":"10.1074\/jbc.M112.370585","article-title":"Autophagy-related gene 7 (ATG7) and reactive oxygen species\/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma","volume":"287","author":"Gong","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0560","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3892\/ijo.2013.1952","article-title":"Tetrandrine induces cell death in SAS human oral cancer cells through caspase activation-dependent apoptosis and LC3-I and LC3-II activation-dependent autophagy","volume":"43","author":"Huang","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0565","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.18632\/oncotarget.3505","article-title":"Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2017.10.116_bib0570","first-page":"113","article-title":"Autophagy: a barrier or an adaptive response to cancer","volume":"1603","author":"Ogier-Denis","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2017.10.116_bib0575","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3858\/emm.2012.44.2.033","article-title":"Autophagy and cancer","volume":"44","author":"Choi","year":"2012","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0580","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1038\/cddis.2014.84","article-title":"Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells","volume":"5","author":"Qiu","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2017.10.116_bib0585","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1523-1755.2004.00500.x","article-title":"Activation of ERK or inhibition of JNK ameliorates H2O2 cytotoxicity in mouse renal proximal tubule cells","volume":"65","author":"Arany","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2017.10.116_bib0590","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/0008-5472.CAN-06-2265","article-title":"Bcl-2 protects endothelial cells against \u03b3-radiation via a Raf\u2013MEK\u2013ERK\u2013survivin signaling pathway that is independent of cytochrome c release","volume":"67","author":"Kumar","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0595","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1046\/j.1471-4159.2001.00085.x","article-title":"Lipid constituents in oligodendroglial cells alter susceptibility to H2O2-induced apoptotic cell death via ERK activation","volume":"76","author":"Brand","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2017.10.116_bib0600","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1021\/tx0200663","article-title":"Mitogen-activated protein kinases contribute to reactive oxygen species-induced cell death in renal proximal tubule epithelial cells","volume":"15","author":"Ramachandiran","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0605","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the wnt pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0610","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1126\/scisignal.2004114","article-title":"Wnt-er migration: the confusing role of \u03b2-catenin in melanoma metastasis","volume":"6","author":"Webster","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biopha.2017.10.116_bib0615","doi-asserted-by":"crossref","first-page":"a008078","DOI":"10.1101\/cshperspect.a008078","article-title":"Wnt signaling and injury repair","volume":"4","author":"Whyte","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0620","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1101\/gad.14.15.1837","article-title":"Wnt signaling and cancer","volume":"14","author":"Polakis","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2017.10.116_bib0625","doi-asserted-by":"crossref","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","article-title":"Wnt signaling in cancer","volume":"4","author":"Polakis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0630","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2011.12.001","article-title":"Dysregulation of Wnt\/\u03b2-catenin signaling in gastrointestinal cancers","volume":"142","author":"White","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2017.10.116_bib0635","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/mol.110.068668","article-title":"Tetrandrine inhibits Wnt\/\u03b2-catenin signaling and suppresses tumor growth of human colorectal cancer","volume":"79","author":"He","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0640","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3892\/ijo.2014.2800","article-title":"The role of IGFBP-5 in mediating the anti-proliferation effect of tetrandrine in human colon cancer cells","volume":"46","author":"Wu","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0645","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1631\/jzus.B1200021","article-title":"Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl\/\u03b2-catenin axis","volume":"13","author":"Xu","year":"2012","journal-title":"J. Zhejiang Univ.\u2013Sci. B (Biomed. Biotechnol.)"},{"key":"10.1016\/j.biopha.2017.10.116_bib0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2011.01.022","article-title":"Combination of tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo","volume":"304","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.10.116_bib0655","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"5","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0660","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1677\/erc.1.01026","article-title":"The mechanism and managements of hormone-therapy resistance in breast and prostate cancers","volume":"12","author":"Rau","year":"2005","journal-title":"Endocr.\u2013Relat. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0665","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0670","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00001813-199803000-00008","article-title":"The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein","volume":"9","author":"Choi","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2017.10.116_bib0675","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0959-8049(01)00356-2","article-title":"The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7\/adr cells","volume":"38","author":"Fu","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0680","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-003-0742-5","article-title":"Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance","volume":"53","author":"Fu","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0685","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00432-009-0704-3","article-title":"Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription","volume":"136","author":"Shen","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0690","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.phymed.2014.04.029","article-title":"Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells","volume":"21","author":"Sun","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2017.10.116_bib0695","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3892\/or.2012.1999","article-title":"Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein","volume":"28","author":"Wang","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2017.10.116_bib0700","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.leukres.2005.08.005","article-title":"Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia","volume":"30","author":"Xu","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0705","first-page":"1953","article-title":"In vitro and in vivo characterizations of tetrandrine on the reversal of p-glycoprotein-mediated drug resistance to paclitaxel","volume":"25","author":"Zhu","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0710","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.10.116_bib0715","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2017.10.116_bib0720","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-007-0420-0","article-title":"Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice","volume":"60","author":"Dai","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0725","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejpb.2010.04.016","article-title":"Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinaseand caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells\u2013a possible Trojan strategy against cancer","volume":"75","author":"Li","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2017.10.116_bib0730","doi-asserted-by":"crossref","first-page":"e24172","DOI":"10.1371\/journal.pone.0024172","article-title":"Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2017.10.116_bib0735","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1208\/s12249-011-9665-3","article-title":"Preparation characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine","volume":"12","author":"Li","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2017.10.116_bib0740","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.2147\/IJN.S34886","article-title":"Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer","volume":"7","author":"Li","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2017.10.116_bib0745","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/mp2002736","article-title":"Paclitaxel\/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on oxidation therapy","volume":"9","author":"Li","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2017.10.116_bib0750","first-page":"231","article-title":"An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(\u03b5-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion","volume":"9","author":"Xu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2017.10.116_bib0755","doi-asserted-by":"crossref","DOI":"10.1038\/srep20867","article-title":"Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles","volume":"6","author":"Rodzinski","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2017.10.116_bib0760","first-page":"4169","article-title":"Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers","volume":"8","author":"Zhao","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2017.10.116_bib0765","doi-asserted-by":"crossref","first-page":"28","DOI":"10.59566\/IJBS.2012.8028","article-title":"Tetrandrine combined with gemcitabine and cisplatin for patients with advanced non-small cell lung cancer improve efficacy","volume":"8","author":"Liu","year":"2012","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2017.10.116_bib0770","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0147-6513(82)90034-3","article-title":"Studies of the chronic toxicity of tetrandrine in dogs: an inhibitor of silicosis","volume":"6","author":"Tainlin","year":"1982","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.biopha.2017.10.116_bib0775","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11655-015-2303-2","article-title":"Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB\/c Mice","volume":"22","author":"Jian-ping","year":"2016","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.biopha.2017.10.116_bib0780","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jss.2010.10.034","article-title":"Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells","volume":"166","author":"Li","year":"2011","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2017.10.116_bib0785","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bcp.2004.01.018","article-title":"Tetrandrine-induced apoptosis is mediated by activation of caspases and PKC-\u03b4 in U937 cells","volume":"67","author":"Jang","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0790","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0378-8741(02)00082-X","article-title":"Inhibition of proliferation and induction of apoptosis by tetrandrine in HepG2 cells","volume":"81","author":"Yoo","year":"2002","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.biopha.2017.10.116_bib0795","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/tox.22238","article-title":"Tetrandrine induces programmed cell death in human oral cancer CAL 27 cells through the reactive oxygen species production and caspase-dependent pathways and associated with Beclin-1-induced cell autophagy","volume":"32","author":"Lien","year":"2017","journal-title":"Environ. Toxicol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217326628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217326628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:07:22Z","timestamp":1780337242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217326628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":159,"alternative-id":["S0753332217326628"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.10.116","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetrandrine and cancer \u2013 An overview on the molecular approach","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.10.116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}